Responses
Clinical/translational cancer immunotherapy
Original research
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial
Compose a Response to This Article
Other responses
No responses have been published for this article.